SCHEMBL16445367

SCHEMBL16445367

O=CC1[CH]CC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1401001 0.85
SCHEMBL6364044 0.83
SCHEMBL385626 0.72
SCHEMBL823130 0.69
SCHEMBL6629206 0.68
SCHEMBL18499412 0.67
SCHEMBL261785 0.67
SCHEMBL12087107 0.64
SCHEMBL261789 0.64
SCHEMBL9244981 0.62

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101258152-A Pyridopyrimidine derivatives as PDE4 inhibitors for the treatment of inflammatory and immune diseases ASTRAZENECA AB (SE) 2008-09-03 CN claimed
CN-1290165-A Benzothiazole Protein tyrosine kinase inhibitors BRISTOL MYERS SQUIBB CO (US) 2001-04-04 CN claimed
US-20230158017-A1 METHODS FOR TREATING DEPRESSIVE SYMPTOMS JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT 2023-05-25 US disclosed
US-11534436-B2 Methods for treating depressive symptoms ALKERMES PHARMA IRELAND LIMITED (IE) 2022-12-27 US disclosed
EP-3781574-A1 MACROCYCLIC SPIROETHERS AS MCL-1 INHIBITORS Ascentage Pharma (Suzhou) Co., Ltd. (CN) 2021-02-24 EP disclosed
US-20210000818-A1 METHODS FOR TREATING DEPRESSIVE SYMPTOMS JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT 2021-01-07 US disclosed
US-10752592-B2 Morphan and morphinan analogues, and methods of use ALKERMES PHARMA IRELAND LIMITED (IE) 2020-08-25 US disclosed
US-10736890-B2 Methods for treating depressive symptoms ALKERMES PHARMA IRELAND LIMITED (IE) 2020-08-11 US disclosed
WO-2020147802-A1 MACROCYCLIC SPIROETHERS AS MCL-1 INHIBITORS ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) 2020-07-23 WO disclosed
EP-3004114-B1 MORPHAN AND MORPHINAN ANALOGUES, AND METHODS OF USE ALKERMES PHARMA IRELAND LTD (IE) 2019-12-25 EP disclosed
US-20190218185-A1 Morphan And Morphinan Analogues, And Methods Of Use JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT 2019-07-18 US disclosed
CN-101495152-A Preparation of polymer conjugates of vla-4 antagonists via a mitsunobu' s reaction ELAN PHARM INC (US) 2009-07-29 CN disclosed
CN-101432129-A Novel compounds that are useful for improving pharmacokinetics ABBOTT LAB (US) 2009-05-13 CN disclosed
CN-101405265-A Amido compounds and their use as pharmaceuticals INCYTE CORP (US) 2009-04-08 CN disclosed
CN-101309922-A Amino-aza-adamantane derivatives and methods of use ABBOTT LAB (US) 2008-11-19 CN disclosed
CN-101258152-A Pyridopyrimidine derivatives as PDE4 inhibitors for the treatment of inflammatory and immune diseases ASTRAZENECA AB (SE) 2008-09-03 CN disclosed
CN-101142172-A Inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1 enzyme ABBOTT LAB (US) 2008-03-12 CN disclosed
CN-101137616-A Inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1 enzyme ABBOTT LAB (US) 2008-03-05 CN disclosed
CN-1279026-C Prostaglandin endoperoxide H synthase biosynthesis inhibitors ABBOTT LAB (US) 2006-10-11 CN disclosed
CN-1342149-A Prostaglandin endoperoxide H synthase biosynthesis inhibitors ABBOTT LAB (US) 2002-03-27 CN disclosed